中国肺癌杂志2016，Vol.19Issue(9)：600-606,7.DOI:10.3779/j.issn.1009-3419.2016.09.08
晚期NSCLC患者EGFR-TKI治疗过程中血清多肽变化及其临床意义的探索性研究
Preliminary Study of Differentially Expressed Serum Peptides of Advanced NSCLC Patients Responsive to EGFR-TKI and Their Clinical Signiifcance
王子赫 1汤传昊 1刘毅 2许彬 3秦海峰 1雷阳阳 1高红军 1何昆 3刘晓晴1
作者信息
- 1. 100071 北京，军事医学科学院附属医院肺部肿瘤科
- 2. 肿瘤学研究室
- 3. 100850北京，国家生物医学分析中心
- 折叠
摘要
Abstract
Background and objectivehTis study aimed at using matrix-assisted laser desorption ionization - time of lfight mass spectrometer (matrix-assisted laser desorption ionization time-of-lfight mass spectrometry, MALDI-TOF-MS) screening the difference serum peptides during epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) treatment and exploring their signiifcance of advanced NSCLC patients.MethodsCollect 102 serum samples from 34 advanced NSCLC pa-tients, which are before TKI treatment, best effect of treatment and atfer progession. Peptides were extracted from the samples and then detected by MALDI-TOF-MS system to get the mass spectra. hTe mass spectra data was analyzed by the Clinpro-ToolTM sotfware to identify the different serum peptides, and then analyzed the clinical signiifcance of peptides.Results Among the 34 patients who received TKI treatment, there were none evaluated as complete response (CR), 11 patients evalu-ated as PR and 23 patients evaluated as stable disease (SD), with the PFS was 8.0 months (95%CI: 6.6-11.2); overall survival (OS) was 11.4 months (95%CI: 10.6-16.5). Atfer detected the serum from three different points of time, the result showed that they were totally different; 87 different peptide peaks were identiifed atfer analysis self-paired serum between the time of best effect and baseline, which included one statistically different [P<0.001, area under curve (AUC)≥0.9] peptide; 96 different peptide peaks were identiifed atfer analysis serum between the time of progression and baseline, which included 3 statistically different (P<0.001, AUC≥0.9) peptides; 115 different peptide peaks were identiifed atfer analysis serum between the time of progression and best effect, which included 4 statistically different (P<0.001, AUC≥0.9) peptides.ConclusionhTeserum peptides of NSCLC patients in the process of TKI treatment are dynamic and the different peptides may be associated with treatment effect and disease progression. However, the features and clinical signiifcance of different peptides need to be vali-dated in the future.关键词
基质辅助激光解析电离飞行时间质谱/肿瘤蛋白质组学/表皮细胞生长因子受体/酪氨酸激酶抑制剂/肺肿瘤Key words
Matrix-assisted laser desorption/ionization time-of-lfight mass spectrometry/Cancer proteomics/Epi-dermal growth factor receptor/Tyrosine kinase inhibitor/Lung neoplasms引用本文复制引用
王子赫,汤传昊,刘毅,许彬,秦海峰,雷阳阳,高红军,何昆,刘晓晴..晚期NSCLC患者EGFR-TKI治疗过程中血清多肽变化及其临床意义的探索性研究[J].中国肺癌杂志,2016,19(9):600-606,7.
